KDMN
Kadmon Holdings, Inc.
Set alert
9.50 0.00 0.00%
9.48 Day range 9.50
52-week range unavailable
- Open
- 9.49
- Prev close
- 9.50
- Mkt cap
- 1.70B
- Vol
- 10.42M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.48
- High
- 9.50
- Forward P/E
- -14.18
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2021
- 50-d avg
- 8.66
- 200-d avg
- 5.35
- 1y target
- 12.10
Key statistics
- Market cap
- 1.70B
- Trailing P/E
- 0.00
- Forward P/E
- -14.18
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 8.66
- 200-day average
- 5.35
Analyst view
Consensus: hold
Hold
Price target (mean) 12.10 +27.4% upside
Now 9.50
- Target (low)
- 9.50
- Target (mean)
- 12.10
- Target (high)
- 20.00
Ratings (0m) 6 4 buy · 1 hold · 1 sell
- Strong buy1
- Buy3
- Hold1
- Sell1
- Strong sell0
Next earnings
Nov 4, 2021
Expected Nov 4, 2021. Consensus EPS estimate -0.20.
Financials — quick view
KDMN Revenue — quarterly 14.71M
KDMN Net income — quarterly -33.62M
KDMN EPS — quarterly -0.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2021 | Sep 1, 2021 | -0.20 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | -0.18 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | -0.19 | — | — | — |
| Mar 4, 2021 | Dec 1, 2020 | -0.17 | — | — | — |
| Nov 5, 2020 | Sep 1, 2020 | -0.16 | — | — | — |
| Aug 6, 2020 | Jun 1, 2020 | -0.13 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 14, 2021 | Mizuho | down | Buy | Neutral |
| Sep 9, 2021 | Jefferies | down | Buy | Hold |
| Jul 19, 2021 | Oppenheimer | main | — | Outperform |
| May 21, 2021 | UBS | init | — | Buy |
| Mar 5, 2021 | Raymond James | main | — | Outperform |
| Nov 11, 2020 | Mizuho | init | — | Buy |
News
- Sanofi completes acquisition of Kadmon
- Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results
- 3 Biotech Stocks That Surged in September
- Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting
- 3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
- KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, HRC, JMP, KDMN, FIBK; Shareholders are Encouraged to Contact the Firm
- SHAREHOLDER ALERT: WeissLaw LLP Reminds ECHO, KDMN, HRC, and DVCR Shareholders About Its Ongoing Investigations
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kadmon Holdings, Inc. - KDMN
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.
Your note
Sign in to keep a note on KDMN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAUER EUGENE A | Director | Purchase | Aug 7, 2017 | 0 |
| FLOWERS CYNTHIA LOUISE | Director | Stock Gift | Nov 7, 2021 | 0 |
| GOLDENTREE ASSET MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 5, 2017 | 0 |
| GORDON STEVEN N | General Counsel | Stock Award(Grant) | Sep 27, 2018 | 86,625 |
| KIRSCH ARTHUR S | Director | Stock Award(Grant) | May 13, 2021 | 30,000 |
| LOEB DANIEL S | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 12, 2017 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 9.18% | 15,711,334 | 60.80M | Jun 29, 2021 |
| Blackrock Inc. | 8.65% | 14,798,802 | 128.90M | Sep 29, 2021 |
| State Street Corporation | 6.20% | 10,611,937 | 41.07M | Jun 29, 2021 |
| Point72 Asset Management, L.P. | 6.14% | 10,511,600 | 40.68M | Jun 29, 2021 |
| Avidity Partners Management, LP | 5.43% | 9,294,600 | 35.97M | Jun 29, 2021 |
| Vanguard Group, Inc. (The) | 5.21% | 8,923,234 | 34.53M | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.83% | 4,846,942 | 18.76M | Jun 29, 2021 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.58% | 4,413,114 | 38.44M | Sep 29, 2021 |
| iShares Russell 2000 ETF | 2.31% | 3,951,975 | 34.42M | Sep 29, 2021 |
| BlackRock Health Sciences Trust II | 1.44% | 2,455,865 | 9.50M | Jun 29, 2021 |
| Vanguard Extended Market Index Fund | 1.40% | 2,390,843 | 9.25M | Jun 29, 2021 |
| iShares Russell 2000 Growth ETF | 0.80% | 1,376,780 | 11.99M | Sep 29, 2021 |